Mounjaro vs Ozempic: which works better, and what it costs you
See more of CureMed in your Google results.
These are two popular prescription weight-loss and diabetes drugs that people often compare to each other. This guide compares how well each works, their side effects, and what they actually cost.
For weight loss, tirzepatide (Mounjaro, Zepbound) outperforms semaglutide (Ozempic, Wegovy) across every direct comparison published so far — in the head-to-head SURMOUNT-5 trial, 20.2% of body weight against 13.7% over 72 weeks — but that trial was paid for by tirzepatide's maker, and the difference matters less than whether you can tolerate the drug, afford it long term, and stay on it.
- Tirzepatide acts on two hormone receptors (GIP and GLP-1); semaglutide acts on one. That mechanistic difference is the likely reason for the efficacy gap.
- A 2025 meta-analysis of 28,980 people found greater weight loss with tirzepatide — but only two of its seven studies were randomised, and heterogeneity was extreme (I² above 90%).
- The one randomised head-to-head trial, SURMOUNT-5 (751 adults, 72 weeks), found 20.2% weight loss with tirzepatide against 13.7% with semaglutide. It was open-label and funded by Eli Lilly, which makes tirzepatide — as was the most-quoted indirect comparison (4.79%). That does not make either wrong; it does mean neither is independent.
- Side-effect profiles are broadly similar: mostly gastrointestinal, mostly early, mostly dose-dependent.
- Both regain weight after stopping. Neither is a course of treatment; both are ongoing therapy.
CureMed grades this on human trial evidence; animal data never raises a grade.
Which GLP-1 drug is most effective for weight loss? Mounjaro vs Ozempic
Tirzepatide beats semaglutide for weight loss, but the size of the gap depends on who measured it: 4.79% in an industry-authored indirect comparison, 1.33% at six months in an independent meta-analysis of 29,000 people, 20.2% vs 13.7% at 72 weeks in SURMOUNT-5, the head-to-head trial funded by Lilly. CureMed ranks the two by what you are optimising for.
The same two molecules, four brand names
What is actually being compared
| Brand | Molecule | Approved for | Acts on |
|---|---|---|---|
| Mounjaro | Tirzepatide | Type 2 diabetes | GIP + GLP-1 receptors |
| Zepbound | Tirzepatide | Weight management | GIP + GLP-1 receptors |
| Ozempic | Semaglutide | Type 2 diabetes | GLP-1 receptor |
| Wegovy | Semaglutide | Weight management | GLP-1 receptor |
Tirzepatide is a dual agonist: it activates the GIP receptor as well as the GLP-1 receptor. Semaglutide activates GLP-1 alone. That extra mechanism is the most plausible explanation for the efficacy difference seen in the data, and it is also why the two drugs are not interchangeable in the way two statins might be.
What the head-to-head evidence actually shows
Three pieces of evidence carry most of the weight here. All three point the same direction; only one is a randomised trial that put the two drugs side by side, and the same company paid for two of them.
The direct comparisons
| Study | Design | Population | Finding |
|---|---|---|---|
| SURMOUNT-5 (N Engl J Med, 2025) | Randomised, open-label phase 3b trial; maximum tolerated dose of each drug for 72 weeks | 751 adults with obesity, without type 2 diabetes | Tirzepatide −20.2% vs semaglutide −13.7%: 6.5 percentage points more weight loss |
| Cureus, 2025 | Meta-analysis of 7 direct-comparison studies (2 randomised, 5 observational) | 28,980 adults with overweight or obesity | Tirzepatide superior; ~1.33% greater weight reduction at 6 months |
| Diabetes Obes Metab, 2025 | Indirect comparison of SURMOUNT-2 and STEP 2 | Adults with obesity and type 2 diabetes | Tirzepatide 15 mg: 4.79% greater weight reduction than semaglutide 2.4 mg |
What that adds up to
- Direction: tirzepatide produces more weight loss than semaglutide. This is consistent across every comparison published.
- Magnitude: from about 1.3 percentage points of body weight (pooled data at six months) to 6.5 points (SURMOUNT-5 at 72 weeks), depending on dose, duration and study design. None of these comparisons used semaglutide's newer 7.2 mg dose (Wegovy HD, FDA-approved in March 2026), which produced about 19–21% weight loss in the STEP UP trial, with more skin-sensation side effects than 2.4 mg.
- Certainty: good on direction, moderate on size. The one randomised head-to-head trial was open-label and funded by the maker of tirzepatide; no independent randomised trial has compared the two.
Side effects: more similar than different
Both drugs share a side-effect profile driven by the same mechanism — slowed gastric emptying and appetite suppression. Most effects appear during dose escalation and settle; the ones that matter clinically are rarer and worth knowing by name.
Reported effects, both molecules
| Effect | Frequency | What to do |
|---|---|---|
| Nausea, vomiting | Common, especially when escalating dose | Usually settles; slower titration helps |
| Diarrhoea or constipation | Common | Manageable; tell your prescriber if persistent |
| Reduced appetite, early fullness | Expected — it is the mechanism | Prioritise protein to limit muscle loss |
| Gallbladder problems | Uncommon | Seek care for severe right-sided abdominal pain |
| Pancreatitis | Rare | Severe persistent abdominal pain is an emergency |
| Muscle loss alongside fat loss | Consistently observed | Resistance training and adequate protein |
Cost, coverage and the part people underestimate
Both are expensive without insurance, and coverage in the United States commonly depends on whether you are prescribed the diabetes brand or the weight-management brand. The larger financial question is not the monthly price but the duration: these are ongoing therapies, and stopping reliably reverses the result.
- Insurance is more likely to cover a diabetes indication than a weight indication, which is why prescription choice is often driven by coverage rather than pharmacology.
- Manufacturer savings programmes materially change out-of-pocket cost and are worth checking before assuming a price.
- Compounded versions sold online are not the same product, are not FDA-approved, and carry sourcing and dosing risks that the branded products do not.
- Budget for continuation, not a course. Trials consistently show substantial weight regain after discontinuation.
Which one fits which person
Ranked on: fit for a stated goal, given the current evidence — not a quality league table. Both are effective drugs, and the right answer is frequently decided by tolerability and coverage rather than by efficacy data.
| # | Option | Verdict | Grade |
|---|---|---|---|
| 1 | Maximum weight reduction is the priority | Tirzepatide | — |
| 2 | Cardiovascular risk reduction is the priority | Semaglutide | — |
| 3 | You have struggled with GI side effects before | Either, titrated slowly | — |
| 4 | Cost is the binding constraint | Whichever is covered | — |
- 01
Maximum weight reduction is the priority
TirzepatideEvery published direct comparison favours it, and the mechanistic rationale is coherent. If weight loss is the objective and cost and tolerability permit, this is what the evidence supports.
- 02
Cardiovascular risk reduction is the priority
SemaglutideSemaglutide has the longer track record and a larger body of published cardiovascular outcome data. Where the goal is risk reduction rather than the scale, that history carries weight.
- 03
You have struggled with GI side effects before
Either, titrated slowlyNeither molecule is reliably gentler. Slower escalation matters more than which drug you choose, and it is the single most useful thing to raise with your prescriber.
- 04
Cost is the binding constraint
Whichever is coveredA drug you can stay on for two years beats a marginally better one you stop after four months. Regain after discontinuation makes adherence the dominant variable.
Frequently asked questions
I have a vial labeled "TR60" — is that tirzepatide?
"TR60" is a vendor-assigned dose code (tirzepatide, 60 mg) used by some research-chemical sellers, not a standardized name. Tirzepatide itself is the same active ingredient as the FDA-approved drugs Mounjaro and Zepbound — but a vial bought this way is not the same product: it has none of the manufacturing, purity or dosing oversight that comes with an actual prescription.
Zepbound before and after: what do the trials actually show?
Zepbound and Mounjaro are the same drug, tirzepatide. In SURMOUNT-1 (2,539 adults without diabetes, 72 weeks), average weight loss was 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, against 3.1% on placebo; 57% of the 15 mg group lost 20% or more, and 4.3–7.1% stopped because of side effects (2.6% on placebo). Head to head in SURMOUNT-5 (751 adults, 72 weeks), tirzepatide lost 20.2% against 13.7% on semaglutide — 22.8 kg against 15.0 kg. The after that matters most is what happens when you stop: in SURMOUNT-4, people who had lost 20.9% in 36 weeks and were then switched to placebo regained 14.0% over the next year, while those who continued lost another 5.5%; 89.5% of those who continued kept at least 80% of their loss, against 16.6% of those who stopped.
Mounjaro before and after: what do the results look like month by month?
Slow at first, then steady, then flat. Month 1 is the 2.5 mg starter dose, which the label says is for getting started and is not a maintenance dose. The dose then goes up by 2.5 mg no faster than every four weeks, so the top dose of 15 mg is reached in month 5 at the earliest. By month 3 (week 12) of SURMOUNT-1, about 8 in 10 people who were taking their doses had lost at least 5% of their weight; of the slower 2 in 10, 90% reached 5% by the end of the trial (Ard et al., Diabetes Obes Metab 2025). The loss levels off after about six to eight months: the median time to a plateau was 24 to 36 weeks, later in people with a higher BMI (Horn et al., Clin Obes 2025). At the end, 72 weeks or about 17 months, the average loss on 15 mg was 20.9% counting everyone who started (2,539 adults without diabetes, N Engl J Med 2022). In people with type 2 diabetes — the condition Mounjaro is approved for in the US — the same dose gave 14.7% (SURMOUNT-2, 938 adults, Lancet 2023). These are averages from trials paid for by Eli Lilly, the maker; individual results vary widely.
Stopping Mounjaro: what happens to the weight, and does a lower dose hold it?
One randomised trial tested this directly. In SURMOUNT-MAINTAIN (The Lancet, 2026; 20 US sites; funded by Eli Lilly), 378 adults with obesity who had taken tirzepatide at the full dose (10 or 15 mg a week) for 60 weeks were assigned, for one more year, to keep that dose, step down to 5 mg, or switch to a placebo injection, without knowing which. From the very start to week 112, counting everyone randomised, body weight was 21.9% lower on the full dose, 16.6% lower on 5 mg and 9.9% lower on placebo. From week 84, people who had regained more than half of the lost weight could be given the drug back: 8% on the full dose (11 of 138), 25% on 5 mg (35 of 142) and 67% on placebo (60 of 90). So in this trial a lower dose held more weight off than stopping, and the full dose held the most. These are averages from one trial; stopping or lowering a dose is a decision to make with the prescriber.
What is the GLP agonist titration schedule to minimize nausea and discomfort?
For tirzepatide (Mounjaro, Zepbound) the label's schedule is 2.5 mg once a week for four weeks, then 5 mg, then steps of 2.5 mg after at least four weeks on each dose, up to a maximum of 15 mg. The slow steps exist because nausea, vomiting and diarrhoea are most common while the dose is rising. A prescriber can hold a dose longer or step back down if side effects are hard to tolerate; skipping steps to lose weight faster is the usual reason people feel ill.
Does GLP treatment combined with diet and exercise give the best results?
It is the only way these drugs were tested. In SURMOUNT-1 everyone, on tirzepatide or placebo, also had a reduced-calorie diet (about 500 calories a day under their needs) and was asked to do at least 150 minutes of physical activity a week. The 20.9% average is the result of the drug plus that plan, not of the injection alone. Resistance training and enough protein also limit the share of the loss that comes from muscle.
Is Mounjaro better than Ozempic for weight loss?
On the published evidence, yes. In SURMOUNT-5, the randomised head-to-head trial, people on tirzepatide lost 20.2% of their body weight over 72 weeks against 13.7% on semaglutide. That trial was open-label and funded by Eli Lilly, which makes tirzepatide. Pooled data at six months show a smaller gap (about 1.33%), and an industry-authored indirect comparison put it at 4.79%. Every comparison points the same way; none is both independent and randomised.
Can I switch from Ozempic to Mounjaro?
Switching between GLP-1 medications is done in practice, but the dose does not transfer across — tirzepatide has its own escalation schedule and starting at an equivalent-sounding dose is not appropriate. This is a prescriber decision, not a self-managed one.
Do the side effects differ between them?
Not substantially. Both share a gastrointestinal profile driven by the same mechanism, both are dose-dependent, and both tend to ease after escalation. Individual tolerance varies more than the drugs do, which is why titration speed usually matters more than the choice of molecule.
What happens when you stop taking either one?
Weight is regained. Trials of both molecules show substantial regain after discontinuation, because the drugs suppress appetite while they are being taken and that effect ends when they do. Treat them as ongoing therapy rather than a course, and plan the financial and clinical commitment accordingly.
Are compounded versions the same thing?
No. Compounded semaglutide and tirzepatide are not FDA-approved products, may use different salt forms, and carry sourcing, sterility and dosing risks the branded products do not. The price difference reflects a real difference in oversight.
Keep reading
- NMN: what the human trials actually show
A worked example of how we grade evidence, including where trials disagree.
- How we grade evidence
Why biomarkers alone never reach our top grade.
- Free stack check
Screen a GLP-1 against everything else you take before you start.
More in Therapies
- Retatrutide side effects: every number from the trials, by dose
Nausea hit 42% on the top dose, 13% felt burning skin and 11% quit. Every retatrutide side-effect number from the trials, set against Zepbound.
- Weight-loss peptides compared: semaglutide, tirzepatide, retatrutide and CagriSema ranked by evidence
Semaglutide, tirzepatide, retatrutide and CagriSema ranked by real trial data — including which ones are actually approved and which are still years away.
- Eloralintide: what the first trial shows about Lilly's weekly amylin shot
Eloralintide is Lilly's weekly amylin shot, not a GLP-1. People on 9 mg lost about 20% of their weight in 48 weeks. Not approved; phase 3 runs to 2028.
- Harvard's 'reverse aging' research: what the epigenetic reprogramming studies actually show
A Harvard-linked therapy just became the first cellular reprogramming treatment cleared for human testing. Here's what the mouse data actually showed first.